Bioventus Inc. (BVS)
- Previous Close
4.3100 - Open
4.2300 - Bid 4.1200 x 100
- Ask 4.2000 x 100
- Day's Range
4.1000 - 4.3200 - 52 Week Range
0.8600 - 6.0800 - Volume
118,230 - Avg. Volume
143,403 - Market Cap (intraday)
263.022M - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5400 - Earnings Date May 14, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
www.bioventus.comRecent News: BVS
Performance Overview: BVS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BVS
Valuation Measures
Market Cap
263.02M
Enterprise Value
620.90M
Trailing P/E
--
Forward P/E
34.60
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.51
Price/Book (mrq)
1.89
Enterprise Value/Revenue
1.21
Enterprise Value/EBITDA
-26.91
Financial Highlights
Profitability and Income Statement
Profit Margin
-30.49%
Return on Assets (ttm)
0.12%
Return on Equity (ttm)
-38.27%
Revenue (ttm)
512.34M
Net Income Avi to Common (ttm)
-96.74M
Diluted EPS (ttm)
-1.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
36.96M
Total Debt/Equity (mrq)
190.23%
Levered Free Cash Flow (ttm)
-108.45M